Relationships of P53 and Bak with EPO and EPOR in human colorectal cancer

Anticancer Research

Volumn 29, Issue 10, 2009, Pages 4151-4156

  Baltaziak, Marek ^a   Koda, Mariusz ^a   Wincewicz, Andrzej ^a   Sulkowska, Mariola ^a   Kanczuga Koda, Luiza ^a   Sulkowski, Stanislaw ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Bak; Colorectal cancer; EPO; EPOR; P53

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; PROTEIN BAK; PROTEIN BCL XL; PROTEIN P53;

ADULT; APOPTOSIS; ARTICLE; CANCER CELL; CELL PROTECTION; CELL SURVIVAL; CLINICAL FEATURE; COLORECTAL CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DOWN REGULATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; UPREGULATION;

ADENOCARCINOMA; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; CELL NUCLEUS; COLORECTAL NEOPLASMS; CYTOPLASM; DISEASE-FREE SURVIVAL; ERYTHROPOIETIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM STAGING; RECEPTORS, ERYTHROPOIETIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 71949111022     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Leu JI, Dumont P, Hafey M, Murphy ME and George DL: Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 6: 443-450, 2004. (Pubitemid 38607505)
2. Pietsch CE, Perchiniak E, Canutescu A, Wang G, Dunbrack RL and Murphy ME: Oligomerization of Bak by p53 utilizes conserved residues of the p53 DNA binding domain. J Biol Chem 283: 21294-21304, 2008.
3. Farrell F and Lee A: The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 9: 18-30, 2004. (Pubitemid 39658342)
4. Lappin T: The cellular biology of erythropoietin receptors. Oncologist 1: 15-18, 2003.
5. Jelkmann W, Bohlius J, Hallek M and Sytkowski AJ: The erythropoietin receptor in normal and cancer tissue. Crit Rev Oncol Hematol 67: 39-61, 2008.
6. Renzi MJ, Farrell FX, Bittner A, Galindo JE, Morton M, Trinh H and Jolliffe LK: Erythropoietin induces changes in gene expression in PC-12 cells. Brain Res Mol Brain Res 104: 86-95, 2002. (Pubitemid 34765549)
7. Silva M, Grillot D, Benito A, Richard C, Nunez G and Fernandez-Luna JL: Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood 88: 1576-1582, 1996. (Pubitemid 26307051)
8. Batra S, Perelman N, Luck LR, Shimada H and Malik P: Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest 83: 1477-1487, 2003. (Pubitemid 37267831)
9. Wincewicz A, Sulkowska M, Koda M, Sulkowski S and Kanczuga-Koda L: Hypoxia dependent markers: EPO and EPOR in comparison to HIF-1alpha, GLUT1 and antiapoptotic protein Bcl-xL in colorectal cancer. J Mol Histol, submitted, 2009.
10. Wincewicz A, Sulkowska M, Koda M and Sulkowski S: Cumulative expression of HIF-1-alpha, Bax, Bcl-xL and P53 in human colorectal cancer. Pathology 39: 334-338, 2007. (Pubitemid 46897599)
11. Koda M, Reszec J, Sulkowska M, Kanczuga-Koda L and Sulkowski S: Expression of the insulin-like growth factor-I receptor and proapoptotic Bax and Bak proteins in human colorectal cancer. Ann NY Acad Sci 1030: 377-383, 2004. (Pubitemid 40378936)
12. Chabowska AM, Sulkowska M, Chabowski A, Wincewicz A, Koda M and Sulkowski S: Erythropoietin and erythropoietin receptor in colorectal cancer. Int J Surg Pathol 16: 69-76, 2008.
13. Guzińska-Ustymowicz K, Sulkowska M, Famulski W and Sulkowski S: Tumour 'budding' and its relationship to p53 and Bcl-2 expression in colorectal cancer. Anticancer Res 23: 649-653, 2003. (Pubitemid 36358467)
14. Nita ME, Nagawa H, Tominaga O, Tsuno N, Fujii S, Sasaki S, Fu CG, Takenoue T, Tsuruo T and Muto T: 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins. Br J Cancer 78: 986-992, 1998. (Pubitemid 28463972)
15. Reszeć J, Sulkowska M, Koda M, Kanczuga-Koda L and Sulkowski S: Expression of cell proliferation and apoptosis markers in papillomas and cancers of conjunctiva and eyelid. Ann NY Acad Sci 1030: 419-426, 2004. (Pubitemid 40378941)
16. Lin Y, Brown L, Hedley DW, Barber DL and Benchimol S: The death-promoting activity of P53 can be inhibited by distinct signaling pathways. Blood 100: 3990-4000, 2002. (Pubitemid 35396865)
17. Dolznig H, Habermann B, Stangl K, Deiner EM, Moriggl R, Beug H and Müllner EW: Apoptosis protection by the Epo target Bcl-X(L) allows factor-independent differentiation of primary erythroblasts. Curr Biol 12: 1076-1085, 2002. (Pubitemid 34766929)
18. Carvalho G, Lefaucheur C, Cherbonnier C, Métivier D, Chapel A, Pallardy M, Bourgeade MF, Charpentier B, Hirsch F and Kroemer G: Chemosensitization by erythropoietin through inhibition of the NF-kappaB rescue pathway. Oncogene 24: 737-745, 2005. (Pubitemid 40216083)
19. Schottelius, AJ and Dinter H: Cytokines, NF-kappaB, microenvironment, intestinal inflammation and cancer. Cancer Treat Res 130: 67-87, 2006.
20. Acs G, Xu X, Chu C, Acs P and Verma A: Prognostic significance of erythropoietin expression in human endometrial carcinoma. Cancer 100: 2376-2386, 2004. (Pubitemid 38657885)
21. Quelle FW, Wang J, Feng J, Wang D, Cleveland JL, Ihle JN and Zambetti GP: Cytokine rescue of P53-dependent apoptosis and cell cycle arrest is mediated by distinct Jak kinase signaling pathways. Genes Dev 12: 1099-1107, 1998. (Pubitemid 28194046)
22. Bachmann K, Pawliska D, Kaifi J, Schurr P, Zörb J, Mann O, Kahl HJ, Izbicki JR and Strate T: P53 is an independent prognostic factor for survival in thyroid cancer. Anticancer Res 27: 3993-3997, 2007.
23. Angiero F, Berenzi A, Benetti A, Rossi E, Del Sordo R, Sidoni A, Stefani M and Dessy E: Expression of p16, p53 and Ki-67 proteins in the progression of epithelial dysplasia of the oral cavity. Anticancer Res 28: 2535-2539, 2008.
24. Zheng H, Tsuneyama K, Cheng C, Takahashi H, Cui Z, Murai Y, Nomoto K and Takano Y: An immunohistochemical study of p53 and Ki-67 in gastrointestinal adenoma and adenocarcinoma using tissue microarray. Anticancer Res 26: 2353-2360, 2006. (Pubitemid 43980201)
25. Pectasides D, Papaxoinis G, Nikolaou M, Valavanis C, Aravantinos G, Fountzilas G, Tamvakis N, Pectasides E, Lekka I, Arapantoni-Dadioti P, Zizi A, Ghiconti I and Economopoulos T: Analysis of 7 immunohistochemical markers in male germ cell tumors demonstrates the prognostic significance of p53 and MIB-1. Anticancer Res 29: 737-744, 2009.
26. Theodoropoulos GE, Karafoka E, Papailiou JG, Stamopoulos P, Zambirinis CP, Bramis K, Panoussopoulos SG, Leandros E and Bramis J: P53 and EGFR expression in colorectal cancer: a reappraisal of 'old' tissue markers in patients with long follow-up. Anticancer Res 29: 785-791, 2009.
27. Wiksten JP, Lundin J, Nordling S, Kokkola A and Haglund C: Comparison of the prognostic value of a panel of tissue tumor markers and established clinicopathological factors in patients with gastric cancer. Anticancer Res 28: 2279-2287, 2008.
28. Remvikos Y, Tominaga O, Hammel P, Laurent-Puig P, Salmon RJ, Dutrillaux B and Thomas G: Increased p53 protein content of colorectal tumours correlates with poor survival. Br J Cancer 66: 758-764, 1992.
29. Sun XF, Carstensen JM, Zhang H, Stål O, Wingren S, Hatschek T and Nordenskjöld B: Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet 340: 1369-1373, 1992.
30. Csejtei A, Tibold A, Varga Z, Koltai K, Ember A, Orsos Z, Feher G, Horvath OP, Ember I and Kiss I: GSTM, GSTT and p53 polymorphisms as modifiers of clinical outcome in colorectal cancer. Anticancer Res 28: 1917-1922, 2008.